EMA Committee Urges Approval of Humira Biosimilar Imraldi to Treat IBDs

EMA Committee Urges Approval of Humira Biosimilar Imraldi to Treat IBDs
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding on marketing authorization for Imraldi (adalimumab), a biosimilar candidate referencing Humira. The EMA committee recommended Imraldi for the treatment of inflammatory bowel diseases (IBDs) like Crohn’s disease, pediatric Crohn’s disease and ulcerative colitis, as well as rheumatoid arthritis, psoriatic

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *